Local and systemic effects of an acute inflammation on eicosanoid generation capacity of polymorphonuclear cells and macrophages.
Acute non-specific inflammation was induced in rats by injection of isologous serum into the pleural cavity. Pleural and peritoneal cells were collected at various times after pleurisy induction and tested for production of leukotriene B4 (LTB4), prostaglandin E2 (PGE2) and prostacyclin (PGI2) after in-vitro stimulation with calcium ionophore A23187. Cells obtained by lavage of pleural and peritoneal cavities of normal rats were used as controls. Increased production of LTB4, PGE2 and PGI2 by pleural cells was observed 3 days after pleurisy induction, but with a significant depression of PGI2 release at 3 h. As the relative proportions of polymorphonuclear cells (PMN) and macrophages in the inflammatory exudate varied during the development of inflammation, these cells were examined separately for LTB4 production. PMN and macrophages contributed equally to the liberation of this mediator in normal and inflamed rats. Similar qualitative and quantitative changes in LTB4 production by pleural cells were observed, irrespective of the type of irritant used (isologous serum, dextran, carrageenan, microcrystals). In contrast, intrapleural injection of saline had no significant effect. In order to determine whether local inflammation may influence mediator release by phagocytic cells at remote sites, peritoneal cells were collected 3 or 72 after pleurisy induction. The production of LTB4, PGE2 and PGI2 was increased at 72 h. Mediator production by peritoneal macrophages was observed in both normal and inflamed rats. In conclusion, acute non-specific inflammation provoked increased arachidonic acid metabolite generation by phagocytes both locally and at a distance: this occurred more than 24 h after pleurisy resolution.
Mathieu
J
J
Département de Radiobiologie, Centre de Recherche du Service de Santé des Armées, La Tronche, France.
Tissot
M
M
Nolibe
D
D
Florentin
I
I
Kergonou
J F
JF
Giroud
J P
JP
D015121:6-Ketoprostaglandin F1 alpha / Q000378:metabolism; D000208:Acute Disease; D000818:Animals; D002478:Cells, Cultured; D015232:Dinoprostone / Q000378:metabolism; D015777:Eicosanoids / Q000378:metabolism*; D011464:Epoprostenol / Q000378:metabolism; D007975:Leukotriene B4 / Q000378:metabolism; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D009504:Neutrophils / Q000187:drug effects / Q000378:metabolism*; D010998:Pleurisy / Q000276:immunology*; D051381:Rats; D011919:Rats, Inbred Strains; D014405:Tuftsin / Q000494:pharmacology
D015777:Eicosanoids; D007975:Leukotriene B4; D015121:6-Ketoprostaglandin F1 alpha; D011464:Epoprostenol; D015232:Dinoprostone; D014405:Tuftsin